Eledon Pharmaceuticals, Inc.
DE ˙ DB ˙ US28617K1016
2,92 € ↓ -0,04 (-1,35%)
2026-06-04
AKTIENPREIS
SecurityDE:2TK / Eledon Pharmaceuticals, Inc.
InstitutionRhumbline Advisers
Latest Disclosed Ownership47,626 shares
Latest Disclosed Value $ 146,683
Rhumbline Advisers reports 6.74% increase in ownership of 2TK / Eledon Pharmaceuticals, Inc.

On May 12, 2026 - Rhumbline Advisers filed a 13F-HR form disclosing ownership of 47,626 shares of Eledon Pharmaceuticals, Inc. (DE:2TK) valued at $109,540 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 44,617 shares of Eledon Pharmaceuticals, Inc.. This represents a change in shares of 6.74% during the quarter. The current value of the position is $139,068 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Eledon Pharmaceuticals COM 28617K101 47,626 3,009 6.74 147 117.91 0.0001
2026-02-13 2025-12-31 13F Eledon Pharmaceuticals COM 28617K101 44,617 -8,947 -16.70 67 -51.45 0.0001
2025-11-06 2025-09-30 13F Eledon Pharmaceuticals COM 28617K101 53,564 -2,486 -4.44 139 -8.61 0.0001
2025-08-12 2025-06-30 13F Eledon Pharmaceuticals COM 28617K101 56,050 56,050 152 0.0001
2017-08-02 2017-06-30 13F TOKAI PHARMACEUTICALS INC COM COM 88907J107 0 -31,937 -100.00 0 -100.00
2017-05-02 2017-03-31 13F TOKAI PHARMACEUTICALS INC COM COM 88907J107 31,937 31,937 27 0.0001
2016-08-11 2016-06-30 13F TOKAI PHARMACEUTICALS COM 88907J107 0 -11,418 -100.00 0 -100.00
2016-05-02 2016-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 11,418 620 5.74 64 -31.91 0.0002
2016-02-03 2015-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 10,798 705 6.99 94 -9.62 0.0003
2015-11-04 2015-09-30 13F TOKAI PHARMACEUTICALS COM 88907J107 10,093 10,093 104 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.